

**Synthesis of 3-(2'-Chloroethoxy)-6-Formyl- $\Delta^{3,5}$ -Pregnadienes. A New Class of Highly Active Anti-Inflammatory Corticosteroids**

In the course of an extensive investigation started some years ago in our laboratories on the action of the Vilsmeier-Haack-type reagent on ketosteroids and derivatives<sup>1</sup>, we have examined the transformations performed by this reagent on cycloethyleneketals derived from  $\Delta^4$ -3-ketosteroids. Some of the compounds obtained showed interesting biological activities.

The 3-cycloethyleneketal<sup>2</sup> (II) of 9 $\alpha$ -fluoro-cortisone-21-acetate<sup>3</sup> (I) was dissolved in trichloroethylene and treated for 3 h at 70°C with the reagent prepared from dimethylformamide and phosphorus oxychloride (DMF-POCl<sub>3</sub>); after decomposition of the resulting complex with aqueous CH<sub>3</sub>COONa and usual work-up, we isolated 3-(2'-chloroethoxy)-6-formyl-9 $\alpha$ -fluoro- $\Delta^{3,5}$ -pregnadien-17 $\alpha$ ,21-diol-11,20-dione-21-acetate<sup>4</sup> (III, m.p. 250–252°;  $\lambda_{max} = 216, 320$  nm ( $\epsilon = 9500, 15,800$ );  $[\alpha]_D - 35^\circ$ ) was obtained; esterification of III with pentanoic acid anhydride gave the amorphous 21-pentanoate V (m.p. 85–95°;  $\lambda_{max} = 216, 317$  nm ( $\epsilon = 11,000, 10,200$ );  $[\alpha]_D + 22^\circ$ ). The 21-desoxo derivative VII (m.p. 223–226°;  $\lambda_{max} = 216, 320$  nm ( $\epsilon = 10,500, 15,200$ );  $[\alpha]_D - 60^\circ$ ) of IV was prepared via the 21-mesylate VI (m.p. 200–205°) and treatment of VI with NaI-CH<sub>3</sub>COOH<sup>11</sup>.


dicarbonyl group<sup>6</sup> rules out the position 4 for the formyl group which thus must be at C-6.

III was also prepared by treating the 3-(2'-chloroethyl)-enoether derived from I<sup>7</sup> (obtained<sup>8</sup> by the action of 2-chloroethyl-orthoformate<sup>9</sup> on I) with the DMF-POCl<sub>3</sub> reagent<sup>10</sup>.

By mild alkaline hydrolysis of III, the corresponding 21-OH derivative (IV, m.p. 220–223°;  $\lambda_{max} = 216, 320$  nm ( $\epsilon = 9500, 15,800$ );  $[\alpha]_D - 35^\circ$ ) was obtained; esterification of IV with pentanoic acid anhydride gave the amorphous 21-pentanoate V (m.p. 85–95°;  $\lambda_{max} = 216, 317$  nm ( $\epsilon = 11,000, 10,200$ );  $[\alpha]_D + 22^\circ$ ). The 21-desoxo derivative VII (m.p. 223–226°;  $\lambda_{max} = 216, 320$  nm ( $\epsilon = 10,500, 15,200$ );  $[\alpha]_D - 60^\circ$ ) of IV was prepared via the 21-mesylate VI (m.p. 200–205°) and treatment of VI with NaI-CH<sub>3</sub>COOH<sup>11</sup>.

Table I

Compound	ED <sub>50</sub> mg granuloma pouch <sup>21</sup>	Local	Os
III	0.006		0.08
IV	0.017		0.046
V	~ 0.051	> 0.300	
VII	0.073		0.100
VIII	0.01		0.2
IX	0.066		0.04
X	0.20		—
XI	0.005		0.053
XII	0.017		0.300
XIII	0.001		0.105
XIV	0.005		0.30
XV	0.012	> 0.100	
XVI	0.052		0.16



Compound	X	Y	R	R'	R''
III	F	OCOCH <sub>3</sub>	O	H	OH
IV	F	OH	O	H	OH
V	F	OCO(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	O	H	OH
VI	F	OSO <sub>2</sub> CH <sub>3</sub>	O	H	OH
VII	F	H	O	H	OH
VIII	Cl	OCOCH <sub>3</sub>	$\alpha$ H, $\beta$ OH	H	OH
IX	F	OCOCH <sub>3</sub>	$\alpha$ H, $\beta$ OH	H	OH
X	F	OH	$\alpha$ H, $\beta$ OH	H	OH
XI	F	OCOCH <sub>3</sub>	$\alpha$ H, $\beta$ OH	CH <sub>3</sub>	OH
XII	Cl	OCOCH <sub>3</sub>	$\alpha$ H, $\beta$ OH	CH <sub>3</sub>	OH
XIII	F	OCOCH <sub>3</sub>	$\alpha$ H, $\beta$ OH	$\cdots$ O $\cdots$ O $\cdots$ C=(CH <sub>3</sub> ) <sub>2</sub>	
XIV	F	OCO(CH <sub>2</sub> ) <sub>3</sub> CH <sub>3</sub>	$\alpha$ H, $\beta$ OH	$\cdots$ O $\cdots$ O $\cdots$ C=(CH <sub>3</sub> ) <sub>2</sub>	
XV	F	H	$\alpha$ H, $\beta$ OH	$\cdots$ O $\cdots$ O $\cdots$ C=(CH <sub>3</sub> ) <sub>2</sub>	
XVI	F	OCOCH <sub>3</sub>	O	$\cdots$ O $\cdots$ O $\cdots$ C=(CH <sub>3</sub> ) <sub>2</sub>	

<sup>1</sup> R. SCIAKY and U. PALLINI, Tetrahedron Letters 1964, 1839; R. SCIAKY and F. MANCINI, Tetrahedron Letters 1965, 137.

<sup>2</sup> W. S. ALLEN, H. M. KISSMAN, S. MAURER, I. RINGLER, and M. J. WEISS, J. mednl pharm. Chem. 5, 133 (1962); the ethyleneketals here described were prepared by the method B reported by A. MARQUET, M. DVOLAITZKY, H. B. KAGAN, L. MAMLOK, C. OUANNES, and J. JACQUES, Bull. Soc. chim. Fr. 1961, 1822.

<sup>3</sup> J. FRIED and E. F. SABO, J. Am. chem. Soc. 79, 1130 (1957).

<sup>4</sup> Satisfactory analytical values have been obtained for all the compounds described; m.p. are taken on a Fisher-Johns block and are uncorrected; rotations are determined at 20–22° in CHCl<sub>3</sub> unless otherwise noted and at the sodium D line; UV-spectra are in 95% ethanol.

<sup>5</sup> R. O. CLINTON, A. J. MANSON, F. W. STONNER, H. C. NEUMANN, R. G. CHRISTIANSEN, R. L. CLARKE, J. H. ACKERMAN, D. F. PAGE, J. W. DEAN, W. B. DICKINSON, and C. CARABATEAS, J. Am. chem. Soc. 83, 1478 (1961).

<sup>6</sup> L. J. BELLAMY, *The Infrared Spectra of Complex Molecules* (J. Wiley and Sons Inc., New York 1958), p. 142.

<sup>7</sup> We have found it to be convenient to use the crude enol ethers for the reaction with the DMF-POCl<sub>3</sub> reagent.

<sup>8</sup> P. L. JULIAN, E. W. MEYER, W. J. KARPEL, and W. COLE, J. Am. chem. Soc. 73, 1982 (1951).

<sup>9</sup> J. HEBKY, Colln Czech. chem. Commun. 13, 442 (1948).

<sup>10</sup> D. BURN, B. ELLIS, P. FEATHER, D. N. KIRK, and V. PETROW, Chem. Ind. 1962, 1907; Tetrahedron 20, 797 (1964).

<sup>11</sup> H. REIMANN, R. S. SMITH, and E. P. OLIVETO, J. org. Chem. 26, 866 (1961).

Table II

	Relative Potency					
	Granuloma pouch			Cotton pellets local <sup>23</sup>	Hepatic glycogen <sup>24</sup>	Inhibition <sup>25,26</sup> of total plasmatic corticosterone (FOH = 1)
	local	os	s.c. <sup>21</sup>			
F-acetate	1	1	1	1	1	<sup>a</sup>
Fluocinolone acetonide	14	3750	786	2.3	4000	220
Fluorometholone	34	1250	250	9.6	500	83
XIII	680	36	23	6.5	130	29

<sup>a</sup> Not determinable because the compound is fluorescent by itself.

In the same manner starting from the corresponding  $\Delta^4$ -3-keto-compounds, the following 3-(2'-chloroethoxy)- $\Delta^{3,5}$ -6-formyl-steroids<sup>12</sup> were prepared by either of the 2 methods described above: 3-(2'-chloroethoxy)-6-formyl-9 $\alpha$ -chloro- $\Delta^{3,5}$ -pregnadien-11 $\beta$ ,17 $\alpha$ ,21-triol-20-one-21-acetate<sup>13</sup> (VIII, m.p. 220–221°;  $\lambda_{max}$  = 216, 318 nm [ $\epsilon$  = 13,500, 15,000];  $[\alpha]_D$  + 38°); its 9 $\alpha$ -fluoro-analogue<sup>13</sup> (IX, m.p. 238–240°;  $\lambda_{max}$  = 216, 324 nm ( $\epsilon$  = 10,500, 13,900);  $[\alpha]_D$  + 21°) which by alkaline hydrolysis gave the corresponding 21-OH derivate (X, m.p. 225–227°;  $\lambda_{max}$  = 216, 324 nm [ $\epsilon$  = 12,840, 18,200];  $[\alpha]_D$  + 10° in dioxane); 3-(2'-chloroethoxy)-6-formyl-9 $\alpha$ -fluoro-16 $\alpha$ -methyl- $\Delta^{3,5}$ -pregnadien-11 $\beta$ ,17 $\alpha$ ,21-triol-20-one-21-acetate<sup>14</sup> (XI, m.p. 228–230°;  $\lambda_{max}$  = 216, 324 nm [ $\epsilon$  = 12,200, 15,900];  $[\alpha]_D$  + 2.5°); its 9 $\alpha$ -chloroanalogue<sup>14</sup> (XII, m.p. 198–203°;  $\lambda_{max}$  = 217, 325 nm [ $\epsilon$  = 12,600, 15,500];  $[\alpha]_D$  + 29°); 3-(2'-chloroethoxy)-6-formyl-9 $\alpha$ -fluoro- $\Delta^{3,5}$ -pregnadien-11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ ,21-tetrol-20-one-16 $\alpha$ ,17 $\alpha$ -acetonide-21-acetate<sup>15</sup> (XIII, m.p. 180–182°;  $\lambda_{max}$  = 216, 324 nm [ $\epsilon$  = 12,100, 17,100];  $[\alpha]_D$  + 26°) and the corresponding 21-pentanoate<sup>16</sup> (XIV, m.p. 103–105°;  $\lambda_{max}$  = 216, 323 nm [ $\epsilon$  = 10,200, 11,700];  $[\alpha]_D$  + 32°); 3-(2'-chloroethoxy)-6-formyl-9 $\alpha$ -fluoro- $\Delta^{3,5}$ -pregnadien-11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ -triol-20-one-16 $\alpha$ ,17 $\alpha$ -acetonide<sup>18</sup> (XV, m.p. 233–235°;  $\lambda_{max}$  = 216, 323 nm [ $\epsilon$  = 10,500, 16,100];  $[\alpha]_D$  + 10°); 3-(2'-chloroethoxy)-6-formyl-9 $\alpha$ -fluoro- $\Delta^{3,5}$ -pregnadien-16 $\alpha$ ,17 $\alpha$ ,21-triol-11,20-dione-16 $\alpha$ ,17 $\alpha$ -acetonide-21-acetate<sup>19</sup> (XVI, m.p. 113–115°;  $\lambda_{max}$  = 215, 323 nm [ $\epsilon$  = 11,400, 14,800];  $[\alpha]_D$  + 19°).

<sup>12</sup> All the 3-(2'-chloroethoxy)-6-formyl- $\Delta^{3,5}$ -steroids showed in the IR, bands at 1640–1652 cm<sup>-1</sup> (medium) and at 1600–1610 cm<sup>-1</sup> (strong); these bands have also been noted by BURN et al.<sup>10</sup>

<sup>13</sup> For the starting  $\Delta^4$ -3-ketones see ref. <sup>3</sup>; the  $\Delta^3$ -3-ethylene-ketal corresponding to IX had m.p. 220–222°;  $[\alpha]_D$  + 126° (dioxane).

<sup>14</sup> For the starting  $\Delta^4$ -3-ketones see G. E. ARTH, J. FRIED, D. B. R. JOHNSTON, D. R. HOFF, L. H. SARETT, R. H. SILBER, H. C. STOERK, and C. A. WINTER, J. Am. chem. Soc. 80, 3161 (1958).

<sup>15</sup> For the starting  $\Delta^4$ -3-ketone see C. E. HOLMUND, L. I. FELDMAN, N. E. RIGLER, B. E. NIELSEN, and R. H. EVANS, J. Am. chem. Soc. 83, 2580 (1961); the corresponding  $\Delta^3$ -3-ethyleneketal was obtained as hemihydrate and had m.p. 145–147°;  $[\alpha]_D$  + 102°.

<sup>16</sup> The starting  $\Delta^4$ -3-ketone was prepared by esterification with pentanoic acid anhydride of 9 $\alpha$ -fluoro- $\Delta^4$ -pregnen-11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ ,21-tetrol-3,20-dione-16 $\alpha$ ,17 $\alpha$ -acetonide<sup>17</sup> and had m.p. 138–140°.

<sup>17</sup> J. FRIED, A. BORMAN, W. B. KESSLER, P. GRABOWICH, and E. F. SABO, J. Am. chem. Soc. 80, 2338 (1958).

<sup>18</sup> For the starting  $\Delta^4$ -3-ketone see S. BERNSTEIN, J. J. BROWN, L. I. FELDMAN, and N. E. RIGLER, J. Am. chem. Soc. 81, 4956 (1959).

The biological data of some of the compounds described are shown in Table I.

From the compounds listed above, XIII has been chosen for a more extensive study; the biological data are summarized in Table II and contrasted with some other corticosteroids.

The inhibitory influence of XIII upon the total plasmatic corticosterone is of a low order when its extremely high local activity is considered; XIII has no sodium-retaining effect and its influence on the glycogenesis is negligible. The unique potency of XIII is represented by the extraordinary dissociation of its local and systemic anti-inflammatory activity.

**Riassunto.** È stata studiata l'azione del reattivo di Vilsmeier-Haack su 3-cicloetilendiossi- $\Delta^5$ -steroidi appartenenti ai corticoidi; è stata così ottenuta una serie di 3-(2'-cloroetossi)-6-formil- $\Delta^{3,5}$ -pregnadieni, alcuni dei quali hanno mostrato notevoli proprietà antiinfiammatorie con una netta dissociazione dell'attività per somministrazione locale e somministrazione sistemica.

G. BALDRATTI, B. CAMERINO, A. CONSONNI, F. FACCIANO, F. MANCINI, U. PALLINI, B. PATELLI, R. SCIAKY, G. K. SUCHOWSKY, and F. TANI

*Istituto Ricerche, S.A. Farmaceutici Italia, Milano (Italy), April 14, 1966.*

<sup>19</sup> The starting  $\Delta^4$ -3-ketone was prepared by oxidation with the Sarett reagent<sup>20</sup> of 9 $\alpha$ -fluoro- $\Delta^4$ -pregnen-11 $\beta$ ,16 $\alpha$ ,17 $\alpha$ ,21-tetrol-3,20-dione-16 $\alpha$ ,17 $\alpha$ -acetonide-21-acetate<sup>15</sup> and had m.p. 218–220°.

<sup>20</sup> G. I. POOS, G. E. ARTH, R. E. BEYLER, and L. H. SARETT, J. Am. chem. Soc. 75, 422 (1953).

<sup>21</sup> The method of ROBERT and NEZAMIS<sup>22</sup> has been slightly modified in our laboratories. The steroids are administered in a single intra-dermal injection suspended in 0.2 ml (0.5 carboxymethyl cellulose, 0.4 Tween 80, 0.9 benzyl alcohol, 0.9 NaCl) or once daily by gavage orally throughout 5 consecutive days. The animals are sacrificed 1 day after the last administration.

<sup>22</sup> A. E. ROBERT and J. E. NEZAMIS, Acta endocr. 25, 105 (1957).

<sup>23</sup> L. G. HERSHBERGER and D. W. CALHOUN, Endocrinology 60, 153 (1957).

<sup>24</sup> R. O. STAFFORD, L. E. BARNES, B. J. BOWMAN, and M. M. MEININGER, Proc. Soc. exp. Biol. 89, 371 (1955).

<sup>25</sup> F. MONCLOA, F. G. PERON, and R. I. DORFMAN, Endocrinology 65, 717 (1959).

<sup>26</sup> H. BRAUNSBURG and V. H. T. JAMES, Analyt. Biochem. 1, 452 (1960).